Roth 'Encouraged' by Early Signs of BL-8040 Activity in AML; Affirms BioLineRx at 'Buy'
Tweet Send to a Friend
Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $8 following presentation of data from its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
